Skip to content

Scholar Rock SRRK Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$49.45M
Arrowhead Research logo
Arrowhead ResearchARWR
$3.16M
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$400M
Cytokinetics logo
CytokineticsCYTK
$182.37M
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$6.14B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Scholar Rock’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's debt issuance proceeds?
Scholar Rock (SRRK) reported debt issuance proceeds of $1K in Q2 2025.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.